Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2026Journal of Translational MedicineOpen Access

Autoimmune hemolytic anemia in the era of immunotherapy: from pathogenesis to therapeutic strategies

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates improved outcomes in autoimmune hemolytic anemia with targeted therapies, suggesting a shift to precision medicine.

Key Points

  • This paper aims to explore the pathogenesis and therapeutic strategies for autoimmune hemolytic anemia in the context of immunotherapy.
  • Overview of treatment options for AIHA including corticosteroids and rituximab
  • Analysis of recent advancements in targeted therapies and their mechanisms
  • Discussion on individualized treatment strategies and biomarkers
  • Targeted therapies have shown promising effects in managing relapsed and refractory AIHA, although specific metrics were not provided.
  • Comparison of novel agents and their mechanism of action highlights advances beyond traditional treatments.
  • Future approaches will emphasize personalized treatment plans guided by biomarkers.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a7d76062b0e0cff3f63f0d7https://doi.org/10.1186/s12967-026-08787-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of autoimmune hemolytic anemia2025
  2. 2Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions2025
  3. 3[Treatment strategies for autoimmune hemolytic anemia].2025
  4. 4[Future directions in the management of warm autoimmune hemolytic anemia].2025
  5. 5Challenges in the diagnosis and management of autoimmune hemolytic anemia: A case-based approach. Experience from a tertiary care hospital in the Haryana region2024